跳转至内容
Merck
CN

T3067

Sigma-Aldrich

Monoclonal Anti-TRAIL antibody produced in mouse

clone 75411, purified immunoglobulin, lyophilized powder

别名:

Anti-TNF-Related Apoptosis-Inducing Ligand, Anti-TNFSF10

登录查看公司和协议定价

选择尺寸


关于此项目

MDL编号:
UNSPSC代码:
12352203
NACRES:
NA.41
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

mouse

质量水平

偶联物

unconjugated

抗体形式

purified immunoglobulin

抗体产品类型

primary antibodies

克隆

75411, monoclonal

表单

lyophilized powder

种属反应性

human

技术

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 8-25 μg/mL using human brain (occipital cortex) tissue sections
neutralization: 28 ng/mL using L929 mouse fibroblast cell line

同位素/亚型

IgG1

UniProt登记号

储存温度

−20°C

靶向翻译后修饰

unmodified

基因信息

human ... TNFSF10(8743)

一般描述

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) cytokine family. This ligand is a type II transmembrane protein that contains a short cytoplasmic N-terminal domain and a long C-terminal extracellular receptor-binding domain. TRAIL is highly expressed in immune system cells. The TRAIL gene is located on the human chromosome at 3q26.31.

免疫原

purified, NSO-derived, recombinant human TRAIL extracellular domain.

应用

Monoclonal Anti-TRAIL antibody produced in mouse has been used in fluorescence-activated cell sorting (FACS).

生化/生理作用

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to TRAIL 1 & 2 receptors and induces apoptosis. This ligand is involved in the homeostasis of T-cells and natural killer (NK) cells. TRAIL also aids in the T-cell-mediated killing of virus-infected cells and oncogenic transformed cells.

外形

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates.

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

常规特殊物品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

ZhengQiang Yuan et al.
Journal of extracellular vesicles, 6(1), 1265291-1265291 (2017-03-23)
Extracellular vesicles (EVs) are lipid membrane-enclosed nanoparticles released by cells. They mediate intercellular communication by transferring biological molecules and therefore have potential as innovative drug delivery vehicles. TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis of cancer cells. Unfortunately, the clinical
Devalingam Mahalingam et al.
Cancer treatment reviews, 35(3), 280-288 (2009-01-02)
Tumour necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a member of the tumour necrosis factor (TNF) superfamily of cytokines that induces apoptosis upon binding to its death domain-containing transmembrane receptors, death receptors 4 and 5 (DR4, DR5). Importantly
Christina Falschlehner et al.
The international journal of biochemistry & cell biology, 39(7-8), 1462-1475 (2007-04-04)
The TNF-related apoptosis-inducing ligand, TRAIL, has been shown to selectively kill tumour cells. This property has made TRAIL and agonistic antibodies against its death inducing receptors (TRAIL-R1 and TRAIL-R2) to some of the most promising novel biotherapeutic agents for cancer
Shashank Tummala et al.
Artificial cells, nanomedicine, and biotechnology, 44(8), 1835-1850 (2015-12-25)
Conventional chemotherapy majorly lacks clinical application attributed to its inspecificity, adverse effects and inability to penetrate into tumor cells. Hence, the aim of the study was to prepare oxaliplatin solid lipid nanoparticles (OP-SLN) by microemulsion method optimizing it by Box-Behnken
Djamel Aggoune et al.
Oncoscience, 1(1), 57-68 (2015-01-17)
Tyrosine kinase inhibitors (TKIs) have profoundly changed the natural history of chronic myeloid leukemia (CML). However, acquired resistance to imatinib, dasatinib or nilotinib (1(st) and 2(nd) generation TKIs), due in part to BCR-ABL1 kinase mutations, has been largely described. These

相关内容

抗体的质量决定了整个免疫检测的成败, 是在选择抗体时首选的考虑因素。基于Sigma®、Chemicon®、Upstate®、Mil l ipore®、 Calbiochem®和Novagen®等子品牌的强强联合,默克在创新的 免疫原设计、免疫、挑选、筛选和验证等方面有着数十年的经验, 创造出许多被广泛使用的抗体,如4G10,Neun,组蛋白修饰等抗 体都是相关领域的“金标”抗体。 我们的技术和科研背景使默克成为高质量抗体的主要设计者和生产 者,而不仅仅是经销商。毋庸置疑,我们的每个小瓶中的抗体都包 含着大量的科学研究成果。

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持